Durvalumab With or Without Olaparib as Maintenance Therapy After First-Line Treatment of Advanced and Recurrent Endometrial Cancer

STATUS

Recruiting
End date

Dec 24, 2024
participants needed

699
sponsor

AstraZeneca

Send

Updated on 19 February 2024

See if I qualify

cancer

immunomodulator

measurable disease

platinum-based chemotherapy

carboplatin

paclitaxel

sarcoma

durvalumab

endometrial carcinoma

cancer treatment

carcinoma

immunomodulators

olaparib

maintenance therapy

cancer therapy

recurrent disease

carcinosarcoma

recurrent endometrial cancer

carboplatin paclitaxel

adjuvant

endometrial cancer

Summary

A study to assess the efficacy and safety of durvalumab in combination with platinum-based chemotherapy (paclitaxel + carboplatin) followed by maintenance durvalumab with or without olaparib for patients with newly diagnosed advanced or recurrent endometrial cancer.

Description

This Phase III study will assess the efficacy and safety of durvalumab in combination with platinum-based chemotherapy (paclitaxel + carboplatin) followed by maintenance durvalumab with or without olaparib for patients with newly diagnosed advanced or recurrent endometrial cancer.

Target patient population: Adult female patients with histologically confirmed diagnosis of epithelial endometrial carcinoma (excluding sarcomas): newly diagnosed Stage III, newly diagnosed Stage IV, or recurrent endometrial cancer

Details

Condition	Endometrial Carcinoma, Uterine Cancer, Uterine Cancer
Age	18-150 years
Treatment	Carboplatin, Paclitaxel, Durvalumab, Olaparib, durvalumab placebo, olaparib placebo
Clinical Study Identifier	NCT04269200
Sponsor	AstraZeneca
Last Modified on	19 February 2024

How understandable was the trial content above?

Hard to understand

Easy to understand

Eligibility		Yes	No	Not Sure
Inclusion Criteria
	Age 18 years at the time of screening and female
	Histologically confirmed diagnosis of epithelial endometrial carcinoma. All histologies, including carcinosarcomas, will be allowed. Sarcomas will not be allowed
	Patient must have endometrial cancer in one of the following categories
	Newly diagnosed Stage III disease (measurable disease per RECIST 1.1 following surgery or diagnostic biopsy)
	Newly diagnosed Stage IV disease (with or without disease following surgery or diagnostic biopsy)
	Recurrence of disease where the potential for cure by surgery alone or in combination is poor
	Nave to first line systemic anti-cancer treatment. For patients with recurrent disease only, prior chemotherapy is allowed only if it was administered in the adjuvant setting and there is at least 12 months from date of last dose of chemotherapy administered to date of subsequent relapse
	FPPE tumor sample must be available for MMR evaluation
	Has Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 within 7 days of starting study treatment
Exclusion Criteria
	History of leptomeningeal carcinomatosis
	Brain metastases or spinal cord compression
	Prior treatment with PARP inhibitors
	Prior immune checkpoint inhibitors or prior treatment with an agent directed to a
	stimulatory or co-inhibitor T-cell receptor other than anti-PD-1, anti-PD-L1
	or anti-PD-L2 agent

How to participate?

Step 1 Connect with a study center

Select a site
Send a message

You have contacted , on

Your message has been sent to the study team at ,

A copy of the message has been sent to your email

What happens next?

You can expect the study team to contact you via email or phone in the next few days.
Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Primary Contact

By sending a message, I agree that my data will be sent to a representative for the selected site and processed in accordance with this website's Privacy Policy (see link in footer).

Step 2 Get screened

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

Step 3 Enroll in the clinical study

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Step 4 Get your study results

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Study Definition

Wikipedia

Durvalumab With or Without Olaparib as Maintenance Therapy After First-Line Treatment of Advanced and Recurrent Endometrial Cancer